Cohort 2: hATG, CsA, EPAG Day 14 to Month 3

( DrugBank: hATG / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
60	再生不良性貧血	1

60. 再生不良性貧血

臨床試験数 : 245 / 薬物数 : 318 - (DrugBank : 86) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 166

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01623167 (ClinicalTrials.gov)	July 2, 2012	14/6/2012	Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia	Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia	Severe Aplastic Anemia	Drug: Cohort 1: hATG, CsA, EPAG Day 14 to Month 6;Drug: Cohort 2: hATG, CsA, EPAG Day 14 to Month 3; ...	National Heart, Lung, and Blood Institute (NHLBI)	Novartis	Recruiting	2 Years	95 Years	All	207	Phase 1/Phase 2	United States

First Previous1Next Last